Antimicrobial Susceptibility Test System Reclassification Effective May 6
This article was originally published in The Gray Sheet
Executive Summary
FDA's 1antimicrobial susceptibility test system final guidance recommends that essential and category agreement should be greater than 89.9%
You may also be interested in...
CDRH-Wide Preamendments Reclassifications Could Finish In 2-3 Years
CDRH's Division of Clinical Laboratory Devices anticipates wrapping up preamendments reclassifications in six to 12 months
FDA Sides With Panel In Downclassifying Antimicrobial Susceptibility Devices
FDA will likely not require additional post-market surveillance from companies manufacturing automated short-term incubation cycle (STIC) antimicrobial susceptibility devices (ASDs), the agency says in the March 8 Federal Register.
Antimicrobial Susceptibility Device Downclassification Supported By Panel
FDA's May 1991 draft guidance on "Review Criteria for the Assessment of Antimicrobial Susceptibility Devices" (ASDs) should be updated for use as a special control prior to downclassification of automated short-term incubation cycle (STIC) ASDs, the agency's Microbiology Devices Panel recommended Feb. 13.